Bausch + Lomb Official Home Page
WEBBausch + Lomb is one of the world's largest suppliers of contact lenses, lens care products, prescription pharmaceuticals, intraocular lenses and other eye surgery products.
Bausch & Lomb - Wikipedia
WEBBausch & Lomb (since 2010 stylized as Bausch + Lomb[2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [4][5] The …
Bausch Health - Wikipedia
WEBBausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Products - Bausch Health
WEBBausch Health offers a diversified portfolio of products, with a core focus in eye health, gastrointestinal diseases and dermatology. We develop, manufacture and market a broad range of branded and generic pharmaceuticals, …
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO ...
WEBMay 18, 2023 · Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (PerfluorohexyloctaneOphthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease. MIEBO is the First and Only...
Eye Health | Bausch Health
WEBPrimarily through Bausch + Lomb, Bausch Health offers a broad line of proprietary pharmaceutical products that treat a number of eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye and retinal diseases.
Who We Are - Bausch Health
WEBWe develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb.
Lomb Completes Acquisition of XIIDRA® - Bausch + Lomb …
WEBSep 29, 2023 · In addition to XIIDRA, Bausch + Lomb’s dry eye offering includes eye and contact lens drops from the company’s consumer brand franchises and its pharmaceutical business, including MIEBO™ (perfluorohexyloctane ophthalmic solution), which launched in the United States earlier this month as the first and only FDA-approved prescription eye ...
Bausch + Lomb and Novaliq Announce U.S. FDA Filing …
WEBSep 6, 2022 · A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). NOV03 has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.
Bausch Health's Bausch + Lomb Announces Completion of the …
WEBSep 29, 2023 · Bausch + Lomb funded the acquisition with the previously announced offering of $1.4 billion aggregate principal amount of 8.375% senior secured notes due 2028 ("Notes") and $500 million of new...
Skip to content